Vaccination campaigns have been rolled out in most countries to increase the vaccination coverage and protect against case mortality during the ongoing pandemic. To evaluate the effectiveness of COVID-19 vaccination, it is vital to disentangle the herd effect from the marginal effect and parameterize them separately in a model. To demonstrate this, we study the relationship between the COVID-19 vaccination coverage and case fatality rate (CFR) based on a U.S. vaccination coverage at county level, with daily records from March 11th, 2021 to Jan 26th, 2022 for 3109 U.S. counties. Using segmented regression, we discovered three breakpoints of the vaccination coverage, at which the herd effects could potentially exist. Controlling for county heterogeneity, we found the size of the marginal effect was not constant but actually enlarged as the vaccination coverage increased, and only the herd effect at the first breakpoint was statistically significant, which implied indirect benefit of vaccination may exist at the early stage of a vaccination campaign. Our results have demonstrated that public health researchers should carefully differentiate and quantify the herd and marginal effects in analyzing vaccination data, to better inform vaccination campaign strategies as well as evaluate vaccination effectiveness.
Whole-genome sequencing (WGS) represents the main technology for SARS-CoV-2 lineage characterization in diagnostic laboratories worldwide. The rapid, near-full-length sequencing of the viral genome is commonly enabled by high-throughput sequencing of PCR amplicons derived from cDNA molecules. Here, we present a new approach, called NASCarD (Nanopore adaptive sampling with carrier DNA), which allows low amount of nucleic acids to be sequenced while selectively enriching for sequences of interest, hence limiting the production of non-target sequences. Using clinical samples positive for SARS-CoV-2 during the Omicron wave, we demonstrate how the method leads to up to >100x coverage of the full genome sequences of the target organism as compared to standard shotgun metatranscriptomics approach. It provides complete and accurate genome sequence reconstruction within seven hours at a competitive cost. The new approach may have applications beyond SARS-CoV-2 sequencing for other DNA or RNA pathogens in clinical samples.
COVID-19 vaccine acceptance research has mostly originated from high-income countries and reasons why youth may not get vaccinated may differ in low-income settings. Understanding vaccination coverage across different population groups and the sociocultural influences in healthcare delivery is important to inform targeted vaccination campaigns. A population-based survey was conducted in 24 communities across three provinces (Harare, Bulawayo and Mashonaland East) in Zimbabwe between October 2021 and June 2022. Youth aged 18 - 24 years were recruited using random sampling. Data on sociodemographic information and COVID-19 vaccination uptake and reasons for non-uptake were collected. A total of 17,682 youth were recruited (n=10,743, 60.8% female). The median age of survey participants was 20 (IQR: 19-22) years. Almost two thirds (n=10,651, 60.2%) of participants reported receiving at least one dose of COVID-19 vaccine. A higher proportion of men than women had been vaccinated (68.9% vs 54.7%), and vaccination prevalence increased with age (<19 years: 57.5%, 20-22: 61.5%, >23: 62.2%). Lack of time to get vaccinated, belief that the vaccine was unsafe and anxiety about side effects (particularly infertility) were the main reasons for not getting vaccinated. Factors associated with vaccination were male sex (OR=1.69, 95%CI:1.58-1.80), increasing age (>22 years: OR=1.12, 95%CI:1.04-1.21), education level (post-secondary: OR=4.34, 95%CI:3.27-5.76), and socioeconomic status (least poor: OR=1.32, 95%CI:1.20-1.47). This study found vaccine inequity across age, sex, educational attainment and socioeconomic status among youth. Strategies should address these inequities by understanding concerns and tailoring vaccine campaigns to specific groups.
Background: The recent COVID-19 epidemic in mainland China is an important issue for studying the prevention and disease control measures and the spread of the COVID-19 epidemic. Following our previous study for the mainland China epidemic during December 31 2021 to 30 April 2022, this paper studies and compares the the mainland China epidemic during December 31 2021 to December 6 2022. Methods: Using differential equations and real word data (both domestic and foreign input infected individuals) modelings and simulates COVID-19 epidemic in mainland China during May 1 2022 to December 6 2022, estimates the transmission rates, the recovery rates, the blocking rates to the symptomatic and the asymptomatic infections, and the died rate of the symptomatic infected individuals. The transmission rates and the recovery rates of the foreign input COVID-19 infected individuals in mainland China have also been studied. Using virtual simulations predict the outcomes of the epidemics. Results: The simulation results were in good agreement with the real word data. (1) The average input transmission rate of the foreign input symptomatic infection individuals was much lower than the average transmission rates of the symptomatic infection causing by the mainland symptomatic and asymptomatic individuals. (2) The average input transmission rate of the foreign input asymptomatic infection individuals was was much lower than the average transmission rate of the asymptomatic infection causing by the mainland symptomatic individuals. (3) The average recovery rates of the foreign input COVID-19 symptomatic and asymptomatic infected individuals were much higher than the average recovery rates of the mainland symptomatic and asymptomatic infected individuals. For the mainland epidemic simulations: (1) If kept the transmission rates, the recovery rates, the death rate and the blocking rates on day 181 (June 30, 2022), the numbers of the current symptomatic and asymptomatic individuals would reduce to about one on day 270 (September 27, 2022). (2) If kept the transmission rates, the recovery rates, the death rate and the blocking rates on day 340 (December 6, 2022) until day 380 (January 15, 2023), the numbers of the current symptomaticand the asymptomatic infected individuals would increase to 37 999 and 224 945, respectively, the cumulative death individuals would increase from 599 to 616. (3)If kept the transmission rates, the recovery rates on day 340, but decreased the blocking rates to 34% and select the death rate to equal to the average death rate during days 104-150, then the simulation showed that on day 380, the numbers of current symptomatic and the asymptomatic infected individuals would increase to about 323 559 095 and 481 270 717, respectively, and the cumulative death individuals would reach about 1 055 607. For the foreign input epidemic simulations: (1) If kept the transmission rates, the recovery rates, and the blocking rates day 242 (August 30, 2022), until day 340, the numbers of the current symptomatic and the asymptomatic infected individuals would decrease to 13 and 430, respectively. (2) If kept the transmission rates, the recovery rates, the death rate and the blocking rates on day 340 until day 380 (January 15 2023), the numbers of the current symptomatic and the asymptomatic infected individuals would decrease and increase to 168 and 1952, respectively. (3) Recommendations on COVID-19 epidemic base on WHO9s technic guidelines and HBV Infection in Chimpanzees are provided. Conclusions: (1) For the mainland individuals9 epidemic, keeping the blocking rates of over 86% and 93% to the symptomatic and asymptomatic infections , and the recovery rates of over 0.119 and 0.112 to the symptomatic and asymptomatic individuals may make the numbers of the current symptomatic and asymptomatic infected individuals to decrease to very low levels in three months. (2) For the foreign input individuals9 epidemic, keeping the transmission rates of under 0.07 to the symptomatic and asymptomatic infections , and the recovery rates of over 0.125 and 0.099 to the symptomatic and asymptomatic individuals may make the numbers of the current symptomatic and asymptomatic infected individuals to decrease to very low levels in four months. (3) After December 6, 2022, decreasing the blocking rates of under 34% to the symptomatic and asymptomatic infections may cause over 1100 millions individuals9 COVID-19 infections and over 1 million COVID-19 infected individuals9 death. (4) It is necessary that administrations implement strict prevent and control strategies to prevent the spread of new COVID-19 variants.
Effect of Selected Types of Breathing Exercises on Different Outcome Measures in Covid-19 Patients - Condition: COVID-19
Intervention: Other: breathing exercise
Sponsor: Basma Mosaad Abd-elrahman Abushady
Completed
Effect Of Calcitriol On Neutrophil To Lymphocytes Ratio And High Sensitivity C-Reactive Protein Covid-19 Patients - Condition: COVID-19
Interventions: Drug: Calcitriol; Other: Placebo
Sponsor: Universitas Sebelas Maret
Completed
Phase I Clinical Trial of Recombinant Variant COVID-19 Vaccine (Sf9 Cell) (WSK-V102) - Condition: COVID-19
Intervention: Biological: Recombinant variant COVID-19 vaccine(Sf9 cell)
Sponsor: WestVac Biopharma Co., Ltd.
Not yet recruiting
A Study to Compare QLS1128 With Placebo in Symptomatic Participants With Mild to Moderate COVID-19 - Condition: COVID-19
Interventions: Drug: QLS1128; Drug: Placebo
Sponsor: Qilu Pharmaceutical Co., Ltd.
Not yet recruiting
Immunogenicity and Reactogenicity of the Beta-variant Recombinant Protein Booster Vaccine (VidPrevtyn Beta, Sanofi) Compared to a Bivalent mRNA Vaccine (Comirnaty Original/Omicron BA.4-5, BioNTech-Pfizer) in Adults Previously Vaccinated With at Least 3 Doses of COVID-19 mRNA Vaccine - Conditions: Vaccine Reaction; COVID-19
Interventions: Biological: Comirnaty® BNT162b2 /Omicron BA.4-5 vaccine (Pfizer-BioNTech); Biological: VidPrevtyn® Beta vaccine (Sanofi/GSK)
Sponsors: Assistance Publique - Hôpitaux de Paris; IREIVAC/COVIREIVAC Network
Not yet recruiting
Study of WPV01 Compared With Placebo in Patients With Mild/Moderate COVID-19 Infection - Condition: COVID-19 Infection
Interventions: Drug: WPV01; Drug: Placebo
Sponsor: Westlake Pharmaceuticals (Hangzhou) Co., Ltd.
Not yet recruiting
ARVAC-A New Recombinant Coronavirus Disease 2019 (COVID-19) - Condition: COVID-19 Vaccine
Interventions: Biological: Gamma Variant RBD-based ARVAC-CG vaccine; Biological: Omicron Variant RBD-based ARVAC-CG vaccine; Biological: Bivalent RBD-based ARVAC-CG vaccine; Other: Placebo
Sponsors: Mónica Edith Lombardo; Universidad Nacional de San Martín (UNSAM); National Council of Scientific and Technical Research, Argentina; Laboratorio Pablo Cassará S.R.L.
Recruiting
A Study of HH-120 Nasal Spray in Close Contacts of Those Diagnosed With COVID-19 - Conditions: COVID-19; SARS-CoV-2 Infection
Intervention: Drug: HH-120 Nasal Spray
Sponsor: Beijing Ditan Hospital
Completed
Oxygen Atomizing Inhalation of EGCG in the Treatment COVID-19 Pneumonia in Cancer Patients - Conditions: COVID-19 Pneumonia; Neoplasms Malignant
Interventions: Drug: EGCG; Drug: Placebo
Sponsor: Shandong Cancer Hospital and Institute
Recruiting
The Use of Photobiomodulation in the Treatment of Oral Complaints of Long COVID-19.A Randomized Controlled Trial. - Conditions: Xerostomia; COVID-19; Long COVID; Persistent COVID-19
Interventions: Combination Product: Institutional standard treatment for xerostomia and Long Covid; Radiation: Photobiomodulation Therapy; Radiation: Placebo Photobiomodulation Therapy
Sponsor: University of Nove de Julho
Recruiting
Acupuncture for Post COVID-19 Fatigue - Conditions: Acupuncture; Post COVID-19 Condition; Fatigue
Interventions: Device: Acupuncture; Device: Sham Acupuncture
Sponsor: Guang’anmen Hospital of China Academy of Chinese Medical Sciences
Not yet recruiting
Balneotherapy for Patients With Post-acute Coronavirus Disease (COVID) Syndrome - Condition: Post-COVID-19 Syndrome
Intervention: Other: Balneotherapy and aquatic exercises
Sponsors: Parc de Salut Mar; Caldes de Montbui’s City Council; Consorcio Centro de Investigación Biomédica en Red (CIBER); European Regional Development Fund
Completed
Clinical and Imaging Biomarkers Associated With Plasma ad Cellular Determinants of Cardiovascular Disease at the Time of COVID 19 - Condition: Cardiovascular Diseases
Intervention: Other: sample blood
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Active, not recruiting
A Study to Assess the Efficacy of HH-120 Nasal Spray for Prevention of SARS-CoV-2 Infection in Adult Close Contacts of Individuals Infected With SARS-CoV-2 - Condition: SARS-CoV-2 Infection
Interventions: Drug: HH-120 nasal spray 1; Drug: HH-120 nasal spray 2; Drug: Placebo Comparator 1; Drug: Placebo Comparator 2
Sponsor: Beijing Ditan Hospital
Completed
Lactoferrin for COVID-19-Induced Taste or Smell Abnormality - Conditions: Covid19; Taste Disorder, Secondary; Taste Disorders; Dysgeusia; Smell Disorder; Ageusia; Anosmia
Intervention: Dietary Supplement: Lactoferrin
Sponsor: Wake Forest University Health Sciences
Withdrawn
Mucosal immunization with Ad5-based vaccines protects Syrian hamsters from challenge with omicron and delta variants of SARS-CoV-2 - SARS-CoV-2 variant clades continue to circumvent antibody responses elicited by vaccination or infection. Current parenteral vaccination strategies reduce illness and hospitalization, yet do not significantly protect against infection by the more recent variants. It is thought that mucosal vaccination strategies may better protect against infection by inducing immunity at the sites of infection, blocking viral transmission more effectively, and significantly inhibiting the evolution of new…
2-Deoxy-D-Glucose: A Novel Pharmacological Agent for Killing Hypoxic Tumor Cells, Oxygen Dependence-Lowering in Covid-19, and Other Pharmacological Activities - The nonmetabolizable glucose analog 2-deoxy-D-glucose (2-DG) has shown promising pharmacological activities, including inhibition of cancerous cell growth and N-glycosylation. It has been used as a glycolysis inhibitor and as a potential energy restriction mimetic agent, inhibiting pathogen-associated molecular patterns. Radioisotope derivatives of 2-DG have applications as tracers. Recently, 2-DG has been used as an anti-COVID-19 drug to lower the need for supplemental oxygen. In the present…
Potential Regulation of NF-κB by Curcumin in Coronavirus-Induced Cytokine Storm and Lung Injury - The current pandemic coronavirus disease-19 (COVID-19) is still a global medical and economic emergency with over 244 million confirmed infections and over 4.95 million deaths by October 2021, in less than 2 years. Severe acute respiratory syndrome (SARS), the Middle East respiratory syndrome coronavirus (MERS), and COVID-19 are three recent coronavirus pandemics with major medical and economic implications. Currently, there is no effective treatment for these infections. One major pathological…
Type I interferon signaling induces a delayed antiproliferative response in Calu-3 cells during SARS-CoV-2 infection - Disease progression during SARS-CoV-2 infection is tightly linked to the fate of lung epithelial cells, with severe cases of COVID-19 characterized by direct injury of the alveolar epithelium and an impairment in its regeneration from progenitor cells. The molecular pathways that govern respiratory epithelial cell death and proliferation during SARS-CoV-2 infection, however, remain poorly understood. We now report a high-throughput CRISPR screen for host genetic modifiers of the survival and…
Induction of systemic, mucosal, and cellular immunity against SARS-CoV-2 in mice vaccinated by trans-airway with a S1 protein combined with a pulmonary surfactant-derived adjuvant SF-10 - CONCLUSIONS: Based on the need for effective systemic, respiratory, and cellular immunity, the S1-SF-10-TA vaccine seems promising mucosal vaccine against respiratory infection of SARS-CoV-2.
SARS-CoV-2-specific antibody responses following BNT162b2 vaccination in individuals with multiple sclerosis receiving different disease-modifying treatments - INTRODUCTION: The study aims to evaluate the concentration of IgG antibodies against the receptor-binding domain of the SARS-CoV-2 spike1 protein (S1RBD) in BNT162b2- vaccinated relapsing-remitting multiple sclerosis (RRMS) individuals receiving disease-modifying treatments (DMTs).
miRNAs derived from milk small extracellular vesicles inhibit porcine epidemic diarrhea virus infection - Porcine epidemic diarrhea virus (PEDV), a member of the genus Alphacoronavirus in the family Coronaviridae, causes acute diarrhea and/or vomiting, dehydration, and high mortality in neonatal piglets. It has caused huge economic losses to animal husbandry worldwide. Current commercial PEDV vaccines do not provide enough protection against variant and evolved virus strains. No specific drugs are available to treat PEDV infection. The development of more effective therapeutic anti-PEDV agents is…
Ovatodiolide inhibits SARS-CoV-2 replication and ameliorates pulmonary fibrosis through suppression of the TGF-β/TβRs signaling pathway - Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection continues to pose threats to public health. The clinical manifestations of lung pathology in COVID-19 patients include sustained inflammation and pulmonary fibrosis. The macrocyclic diterpenoid ovatodiolide (OVA) has been reported to have anti-inflammatory, anti-cancer, anti-allergic, and analgesic activities. Here, we investigated the pharmacological mechanism of OVA in suppressing SARS-CoV-2 infection and pulmonary fibrosis…
Neutralizing activity and 3-month durability of tixagevimab and cilgavimab prophylaxis against Omicron sublineages in transplant recipients - Neutralizing antibody (nAb) responses are attenuated in solid organ transplant recipients (SOTRs) despite severe acute respiratory syndrome-coronavirus-2 vaccination. Preexposure prophylaxis (PrEP) with the antibody combination tixagevimab and cilgavimab (T+C) might augment immunoprotection, yet in vitro activity and durability against Omicron sublineages BA.4/5 in fully vaccinated SOTRs have not been delineated. Vaccinated SOTRs, who received 300 + 300 mg T+C (ie, full dose), within a…
Therapeutic potential of salicylamide derivatives for combating viral infections - Since time immemorial human beings have constantly been fighting against viral infections. The ongoing and devastating coronavirus disease 2019 pandemic represents one of the most severe and most significant public health emergencies in human history, highlighting an urgent need to develop broad-spectrum antiviral agents. Salicylamide (2-hydroxybenzamide) derivatives, represented by niclosamide and nitazoxanide, inhibit the replication of a broad range of RNA and DNA viruses such as flavivirus,…
Antimicrobial and Antiviral Properties of Triclosan-Containing Polymer Composite: Aging Effects of pH, UV, and Sunlight Exposure - The present study deals with the synthesis and characterization of a polymer composite based on an unsaturated ester loaded with 5 wt.% triclosan, produced by co-mixing on an automated hardware system. The polymer composite’s non-porous structure and chemical composition make it an ideal material for surface disinfection and antimicrobial protection. According to the findings, the polymer composite effectively inhibited (100%) the growth of Staphylococcus aureus 6538-P under exposure to…
Triterpene Derivatives as Potential Inhibitors of the RBD Spike Protein from SARS-CoV-2: An In Silico Approach - The appearance of a new coronavirus, SARS-CoV-2, in 2019 kicked off an international public health emergency. Although rapid progress in vaccination has reduced the number of deaths, the development of alternative treatments to overcome the disease is still necessary. It is known that the infection begins with the interaction of the spike glycoprotein (at the virus surface) and the angiotensin-converting enzyme 2 cell receptor (ACE2). Therefore, a straightforward solution for promoting virus…
High Plasma tPAPAI-1C Levels May Be Related to a Poor Prognosis in Patients with Severe or Critical COVID-19: A Single-Center Retrospective Study - Severe novel coronavirus disease 2019 (COVID-19) patients have a high incidence of thrombotic complications and mortality. The pathophysiology of coagulopathy involves fibrinolytic system impairment and vascular endothelial damage. This study examined coagulation and fibrinolytic markers as outcome predictors. In an observational study of 164 COVID-19 patients admitted to our emergency intensive care unit, hematological parameters on days 1, 3, 5, and 7 were retrospectively compared between…
Porcine Epidemic Diarrhea Virus and Its nsp14 Suppress ER Stress Induced GRP78 - Porcine epidemic diarrhea virus (PEDV), a member of the α-coronavirus genus, can cause vomiting, diarrhea, and dehydration in piglets. Neonatal piglets infected with PEDV have a mortality rate as high as 100%. PEDV has caused substantial economic losses to the pork industry. Endoplasmic reticulum (ER) stress, which can alleviate the accumulation of unfolded or misfolded proteins in ER, involves in coronavirus infection. Previous studies have indicated that ER stress could inhibit the replication…
R-Propranolol Has Broad-Spectrum Anti-Coronavirus Activity and Suppresses Factors Involved in Pathogenic Angiogenesis - The SARS-CoV-2 pandemic highlighted the need for broad-spectrum antivirals to increase our preparedness. Patients often require treatment by the time that blocking virus replication is less effective. Therefore, therapy should not only aim to inhibit the virus, but also to suppress pathogenic host responses, e.g., leading to microvascular changes and pulmonary damage. Clinical studies have previously linked SARS-CoV-2 infection to pathogenic intussusceptive angiogenesis in the lungs, involving…